ATE359766T1 - Pharmazeutische darreichungsformen, welche einen tablettenkern mit einer bruchfestigkeit unter 38n/qcm und einen überzug zum schutz des weichen kerns enthalten - Google Patents

Pharmazeutische darreichungsformen, welche einen tablettenkern mit einer bruchfestigkeit unter 38n/qcm und einen überzug zum schutz des weichen kerns enthalten

Info

Publication number
ATE359766T1
ATE359766T1 AT03706749T AT03706749T ATE359766T1 AT E359766 T1 ATE359766 T1 AT E359766T1 AT 03706749 T AT03706749 T AT 03706749T AT 03706749 T AT03706749 T AT 03706749T AT E359766 T1 ATE359766 T1 AT E359766T1
Authority
AT
Austria
Prior art keywords
tablet core
coating
pharmaceutical dosage
core
qcm
Prior art date
Application number
AT03706749T
Other languages
English (en)
Inventor
Wei Tian
John Langridge
Marshall Whiteman
Original Assignee
Phoqus Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phoqus Pharmaceuticals Ltd filed Critical Phoqus Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE359766T1 publication Critical patent/ATE359766T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03706749T 2002-02-28 2003-02-28 Pharmazeutische darreichungsformen, welche einen tablettenkern mit einer bruchfestigkeit unter 38n/qcm und einen überzug zum schutz des weichen kerns enthalten ATE359766T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0204772.8A GB0204772D0 (en) 2002-02-28 2002-02-28 Pharmaceutical dosage forms

Publications (1)

Publication Number Publication Date
ATE359766T1 true ATE359766T1 (de) 2007-05-15

Family

ID=9932020

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03706749T ATE359766T1 (de) 2002-02-28 2003-02-28 Pharmazeutische darreichungsformen, welche einen tablettenkern mit einer bruchfestigkeit unter 38n/qcm und einen überzug zum schutz des weichen kerns enthalten

Country Status (12)

Country Link
US (1) US20050142199A1 (de)
EP (1) EP1478350B1 (de)
JP (1) JP2005524654A (de)
AT (1) ATE359766T1 (de)
AU (1) AU2003208461A1 (de)
CA (1) CA2476171A1 (de)
DE (1) DE60313296T2 (de)
ES (1) ES2282604T3 (de)
GB (1) GB0204772D0 (de)
PT (1) PT1478350E (de)
WO (1) WO2003072086A1 (de)
ZA (1) ZA200406194B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040109889A1 (en) 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
CA2549195A1 (en) * 2003-12-09 2005-06-23 Spherics, Inc. Bioadhesive polymers with catechol functionality
US7553377B1 (en) 2004-04-27 2009-06-30 Advanced Cardiovascular Systems, Inc. Apparatus and method for electrostatic coating of an abluminal stent surface
US7390524B1 (en) 2004-05-20 2008-06-24 Advanced Cardiovascular Systems, Inc. Method for electrostatic spraying of an abluminal stent surface
US20080311191A1 (en) * 2004-08-27 2008-12-18 Avinash Nangia Multi-Layer Tablets and Bioadhesive Dosage Forms
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US8481565B2 (en) * 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
EP1976522B2 (de) 2005-12-30 2019-07-03 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische zusammensetzung mit montelukast
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
WO2009089545A1 (en) * 2008-01-11 2009-07-16 Reata Pharmaceuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
TWI455733B (zh) 2009-03-30 2014-10-11 Toray Industries 口腔內崩壞性被覆錠劑
US8968456B2 (en) * 2009-08-28 2015-03-03 Hercules Incorporated Film coating composition from solid powder hydrophobic compounds
US8663671B2 (en) 2009-11-05 2014-03-04 Philip Morris Usa Inc. Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity
CN102008393B (zh) * 2010-11-12 2012-11-28 罗彦凤 干法包衣设备
BR112019023664A8 (pt) 2017-05-22 2022-07-26 Currahee Holding Company Inc Forma de dosagem em pastilha

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2253164B (en) * 1991-02-22 1994-10-05 Hoechst Uk Ltd Improvements in or relating to electrostatic coating of substrates of medicinal products
ES2096103T3 (es) * 1992-01-13 1997-03-01 Pfizer Preparacion de comprimidos de resistencia incrementada.
US6277409B1 (en) * 2000-02-11 2001-08-21 Mcneil-Ppc, Inc. Protective coating for tablet
GB0117619D0 (en) * 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form

Also Published As

Publication number Publication date
AU2003208461A1 (en) 2003-09-09
PT1478350E (pt) 2007-07-13
EP1478350A1 (de) 2004-11-24
DE60313296D1 (de) 2007-05-31
ES2282604T3 (es) 2007-10-16
WO2003072086A1 (en) 2003-09-04
ZA200406194B (en) 2006-06-28
CA2476171A1 (en) 2003-09-04
EP1478350B1 (de) 2007-04-18
JP2005524654A (ja) 2005-08-18
US20050142199A1 (en) 2005-06-30
GB0204772D0 (en) 2002-04-17
DE60313296T2 (de) 2007-12-27

Similar Documents

Publication Publication Date Title
ATE359766T1 (de) Pharmazeutische darreichungsformen, welche einen tablettenkern mit einer bruchfestigkeit unter 38n/qcm und einen überzug zum schutz des weichen kerns enthalten
AR098808A2 (es) Una forma de dosificación farmacéutica de fusión instantánea que se desintegrará en la boca en un tiempo de 25 segundos
WO2003103637A3 (en) MODIFIED RELEASE MULTIPLE UNIT DRUG DELIVERY SYSTEMS
DK1246622T3 (da) Nye substituerede benzimidazol dosisformer og metoder til deres anvendelse
BR0003158A (pt) Formulação de dosagem oral de derretimentoinstantâneo
ES2191616T3 (es) Polvos pulverizables de fluoropolimeros no fibrilables.
HUP0000138A2 (hu) Szabályozott hatóanyag-leadású opioid analgetikumokat tartalmazó gyógyászati készítmények
EP1366759A4 (de) Tabletten, die in der mundhöhle schnell zerfallen
ES2099275T3 (es) Comprimido multiparticulas de desleimiento rapido.
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
EP1476138B8 (de) Formulierungen mit modifizierter freisetzung von mindestens einer form von tramadol
WO2006002365A3 (en) Microparticles with high loadings of a bioactive agent
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
CA2457361A1 (en) Opioid agonist formulations with releasable and sequestered antagonist
NZ314442A (en) Extended release formulation comprising venlafaxine hydrochloride, film coating composition
GEP20094627B (en) High drug load tablet
RS50937B (sr) Farmaceutska kompozicija koja sadrži metformin i glibenklamid za lečenje šećerne bolesti tipa ii
TNSN05048A1 (en) Inhalation compositions with high drug ratios
CO5640071A2 (es) Composiciones farmaceuticas de atorvastatina
TW200635617A (en) Multiparticulate pharmaceutical form comprising mucoadhesively formulated nucleic acid active ingredients, and a process for producing the pharmaceutical form
MXPA02006603A (es) Forma de dosificacion de nucleo suave, de revestimiento fragil.
WO2005007137A3 (de) Ambroxolhaltige tabletten
MX2010007281A (es) Composiciones farmaceuticas de amlodipina y valsartan.
MX2022000816A (es) Composiciones de pretomanida.
WO2008079343A3 (en) Composition of and method for preparing orally disintegrating tablets containing a high dose of pharmaceutically active ingredients

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1478350

Country of ref document: EP

REN Ceased due to non-payment of the annual fee